{"id":"W3215447362","doi":"10.1053/j.gastro.2021.10.051","title":"Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis","year":2021,"lang":"en","type":"review","venue":"Gastroenterology","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Alcohol Abuse and Alcoholism; National Institute of Environmental Health Sciences; NIHR Newcastle Biomedical Research Centre; Sandoz; Genentech; AstraZeneca; Allergan; Inventiva Pharma; Siemens; Novartis Pharma; European Commission; Innovative Medicines Initiative; Intercept Pharmaceuticals; NGM Biopharmaceuticals; Boehringer Ingelheim; Gilead Sciences; Roche; Novo Nordisk; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Arrien Pharmaceuticals; Novartis; GlaxoSmithKline; National Heart, Lung, and Blood Institute; Shire; Bristol-Myers Squibb; Eli Lilly and Company; Horizon 2020; European Federation of Pharmaceutical Industries and Associations; DOD Peer Reviewed Cancer Research Program; Takeda Pharmaceutical Company; Abbott Laboratories","keywords":"Nonalcoholic steatohepatitis; Medicine; Drug; Steatohepatitis; Drug development; Internal medicine; Pharmacology; Nonalcoholic fatty liver disease; Fatty liver","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01245201,0.00136539,0.004055137,0.003456827,0.0004047642,0.00206259,0.002274346,0.003327935,0.01445591],"category_scores_gemma":[0.01589172,0.000588836,0.005081698,0.002642352,0.0005008806,0.001266207,0.001445019,0.002415711,0.003479714],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002515619,"about_ca_system_score_gemma":0.008091957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003494753,"about_ca_topic_score_gemma":0.009155034,"domain_scores_codex":[0.9951651,0.002197187,0.0009436136,0.0002699665,0.001218059,0.0002061214],"domain_scores_gemma":[0.9928803,0.003188724,0.001550066,0.0001604664,0.002026823,0.0001937273],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001730452,0.0001459982,0.0003401602,0.2110954,0.00440341,0.0001882006,0.0001148269,0.0004528473,0.001387783,0.002953316,0.245434,0.5317535],"study_design_scores_gemma":[0.001755207,0.0004324981,0.001652641,0.2081356,0.01182695,0.0002644191,0.00005759182,0.0001656641,0.0005813374,0.001462791,0.7736153,0.00005004218],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000414095,0.9744748,0.0009044762,0.008041487,0.002731052,0.001294309,0.00249822,0.00005420479,0.009587367],"genre_scores_gemma":[0.004331115,0.9631905,0.003492968,0.01869877,0.001375385,0.001300093,0.002435877,0.00003069632,0.005144638],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01445591,"threshold_uncertainty_score":0.0658533,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07979963252423165,"score_gpt":0.3579071688042244,"score_spread":0.2781075362799927,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}